Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vidutolimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    University of Iowa HCCC Presents Prelim Data from Trial of Vidutolimod
    University of Iowa HCCC Presents Prelim Data from Trial of Vidutolimod

    26 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/26/2451667/0/en/University-of-Iowa-Holden-Comprehensive-Cancer-Center-Presents-Preliminary-Data-from-Clinical-Trial-of-Vidutolimod-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Mee.html

    GLOBENEWSWIRE
    26 May 2022
    Share Share
    Checkmate details troubled future if Regeneron deal fails
    Checkmate details troubled future if Regeneron deal fails

    14 May 2022

    // A. Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/checkmate-details-troubled-future-if-250m-regeneron-merger-does-not-close

    A. Armstrong FIERCEBIOTECH
    14 May 2022
    Share Share
    A promising cancer drug leads Regeneron to reconsider its aversion to M&A
    A promising cancer drug leads Regeneron to reconsider its aversion to M&A

    20 Apr 2022

    // J. Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/regeneron-checkmate-cancer-drug-first-acquisition/622306/

    J. Bell BIOPHARMADIVE
    20 Apr 2022
    Share Share
    Checkmate Pharma Presents Trial Biomarker Data with Vidutolimod at AACR
    Checkmate Pharma Presents Trial Biomarker Data with Vidutolimod at AACR

    08 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/08/2419459/0/en/Checkmate-Pharmaceuticals-Presents-Clinical-Trial-Biomarker-Data-with-Vidutolimod-at-the-2022-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    08 Apr 2022
    Share Share
    Checkmate Presents Data for Phase 1b Study Evaluating Vidutolimod at SITC
    Checkmate Presents Data for Phase 1b Study Evaluating Vidutolimod at SITC

    12 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/12/2333301/0/en/Checkmate-Pharmaceuticals-Presents-Final-Clinical-Data-for-Phase-1b-Study-Evaluating-Vidutolimod-at-The-Society-for-Immunotherapy-of-Cancer-SITC-36th-Annual-Meeting.html

    GLOBENEWSWIRE
    12 Nov 2021
    Share Share